Hopp til hovedinnhold

Ozanimod (Zeposia®)

Publisert:
Sist revidert av:

Kort om

Indikasjon

Informasjonsmateriell

Effekt

Dosering

Bivirkninger

Kontraindikasjoner

Før behandling

Ved første dose

Kontroller under behandling

Seponering

Etter avsluttet behandling

Kilder

Referanser

  1. Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009-20. PubMed  
  2. Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021-33. PubMed  
  3. Zeposia - Summary of Product Characteristics Available from: https://www.ema.europa.eu/documents/product-information/zeposia-epar-product-information_no.pdf.
  4. Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, et al. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. J Clin Pharmacol. 2017;57(8):988-96. PubMed  
  • Hanne Marie Bøe Lunde, spesialist i nevrologi PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med
  • Unn Ljøstad, spesialist i nevrologi, professor PhD